Oramed Pharmaceuticals (ORMP) Competitors $2.15 -0.07 (-3.15%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.24 +0.10 (+4.42%) As of 02/21/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ORMP vs. ATAI, RVNC, PRME, ESPR, RGNX, TRML, MBX, ACB, TERN, and FHTXShould you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include Atai Life Sciences (ATAI), Revance Therapeutics (RVNC), Prime Medicine (PRME), Esperion Therapeutics (ESPR), REGENXBIO (RGNX), Tourmaline Bio (TRML), MBX Biosciences (MBX), Aurora Cannabis (ACB), Terns Pharmaceuticals (TERN), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical products" industry. Oramed Pharmaceuticals vs. Atai Life Sciences Revance Therapeutics Prime Medicine Esperion Therapeutics REGENXBIO Tourmaline Bio MBX Biosciences Aurora Cannabis Terns Pharmaceuticals Foghorn Therapeutics Atai Life Sciences (NASDAQ:ATAI) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, community ranking, profitability, earnings, institutional ownership and risk. Do analysts rate ATAI or ORMP? Atai Life Sciences currently has a consensus target price of $9.00, indicating a potential upside of 352.26%. Given Atai Life Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe Atai Life Sciences is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atai Life Sciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders & institutionals believe in ATAI or ORMP? 28.4% of Atai Life Sciences shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 31.2% of Atai Life Sciences shares are held by insiders. Comparatively, 13.7% of Oramed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has preferable valuation & earnings, ATAI or ORMP? Oramed Pharmaceuticals has higher revenue and earnings than Atai Life Sciences. Atai Life Sciences is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtai Life Sciences$310K1,077.17-$40.22M-$0.81-2.46Oramed Pharmaceuticals$1.34M64.68$5.53M$0.1119.55 Which has more risk and volatility, ATAI or ORMP? Atai Life Sciences has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Does the media prefer ATAI or ORMP? In the previous week, Atai Life Sciences had 5 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 6 mentions for Atai Life Sciences and 1 mentions for Oramed Pharmaceuticals. Atai Life Sciences' average media sentiment score of 0.66 beat Oramed Pharmaceuticals' score of 0.00 indicating that Atai Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Life Sciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oramed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer ATAI or ORMP? Atai Life Sciences received 14 more outperform votes than Oramed Pharmaceuticals when rated by MarketBeat users. However, 72.50% of users gave Oramed Pharmaceuticals an outperform vote while only 66.47% of users gave Atai Life Sciences an outperform vote. CompanyUnderperformOutperformAtai Life SciencesOutperform Votes33366.47% Underperform Votes16833.53% Oramed PharmaceuticalsOutperform Votes31972.50% Underperform Votes12127.50% Is ATAI or ORMP more profitable? Oramed Pharmaceuticals' return on equity of -7.27% beat Atai Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Atai Life SciencesN/A -65.75% -52.71% Oramed Pharmaceuticals N/A -7.27%-6.20% SummaryAtai Life Sciences beats Oramed Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORMP vs. The Competition Export to ExcelMetricOramed PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$89.49M$7.07B$5.85B$9.15BDividend YieldN/A2.76%4.76%3.85%P/E Ratio19.552.5616.5114.19Price / Sales64.68304.55450.0276.60Price / CashN/A65.6738.0134.95Price / Book0.536.717.644.63Net Income$5.53M$138.11M$3.18B$245.69M7 Day Performance-10.42%-2.54%-1.95%-2.68%1 Month Performance-6.93%-2.00%-0.23%-2.16%1 Year Performance-34.85%-5.04%16.69%12.90% Oramed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORMPOramed Pharmaceuticals1.0873 of 5 stars$2.15-3.2%N/A-33.0%$89.49M$1.34M19.5510Analyst DowngradeATAIAtai Life Sciences3.114 of 5 stars$2.30+1.3%$9.00+291.3%+5.9%$385.94M$310,000.00-2.8480Insider TradeNews CoverageGap UpHigh Trading VolumeRVNCRevance Therapeutics4.1959 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500Analyst ForecastPRMEPrime Medicine2.5356 of 5 stars$2.84+9.2%$13.13+362.1%-65.1%$372.49MN/A-1.39234News CoverageESPREsperion Therapeutics4.4488 of 5 stars$1.86-0.5%$6.75+262.9%-30.1%$366.49M$116.33M-2.91200Gap DownRGNXREGENXBIO3.914 of 5 stars$7.30-0.3%$33.45+358.3%-60.5%$361.64M$90.24M-1.45370Analyst RevisionTRMLTourmaline Bio1.7636 of 5 stars$13.83+5.7%$54.00+290.5%-66.2%$354.60MN/A-4.9044MBXMBX Biosciences2.5939 of 5 stars$10.41+15.8%$37.25+257.8%N/A$347.90MN/A0.0036Insider TradeNews CoverageACBAurora Cannabis0.5205 of 5 stars$6.31-4.7%N/A+73.2%$346.17M$200.35M126.231,073Gap UpTERNTerns Pharmaceuticals4.4005 of 5 stars$4.06-0.5%$18.30+350.7%-50.4%$344.86MN/A-3.4440FHTXFoghorn Therapeutics2.6981 of 5 stars$6.13-0.5%$13.17+114.8%-12.4%$340.89M$34.15M-3.19120Positive News Related Companies and Tools Related Companies Atai Life Sciences Competitors Revance Therapeutics Competitors Prime Medicine Competitors Esperion Therapeutics Competitors REGENXBIO Competitors Tourmaline Bio Competitors MBX Biosciences Competitors Aurora Cannabis Competitors Terns Pharmaceuticals Competitors Foghorn Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ORMP) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORMP Stock Alerts